Humana Inc vs Nuscale Power Corporation — how do they compare? Humana Inc trades at $437.2 (market cap $47.61B), while Nuscale Power Corporation trades at $7.42 (market cap $3.15B). The key difference: Humana Inc is far larger — about 15.1× Nuscale Power Corporation's market cap, and Humana Inc pays a 0.89% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Nuscale Power Corporation for 29 Days on average.
| HUM | SMR | |
|---|---|---|
Market Cap | $47.61B | $3.15B |
Volume | 1,827,332 | 38,437,205 |
Sector | Health | Industrials |
52-Week High | $409.85 | $53.43 |
52-Week Low | $163.67 | $7.32 |
Typical Hold Time | 53 Days | 29 Days |
Enterprise Value | $54.97B | $2.08B |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
NuScale Power (SMR) trades at $7.67, down 4.42% today, amid bearish technical signals and negative profitability metrics. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with analyst consensus showing a mixed 50% buy rating but a $11.25 price target. Recent news highlights ongoing legal investigations and competitive pressures in the nuclear energy sector.
The outlook remains challenging with significant operational losses and cash burn, though analyst targets suggest potential upside. Key risks include execution on commercialization, dilution concerns, and intense SMR competition. The stock's future hinges on converting its $1.1 billion cash position into revenue-generating projects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →